Panagene said Thursday that it has completed its patent registration for PANAmp, a molecular diagnostic platform.
The platform has solved one of the biggest problems in gene diagnosis where genes with a specific nucleotide sequence that repeats itself have low amplification efficiency making them hard to detect or have low sensitivity, the company said.
PANAmp platform can effectively control both detection sensitivity and amplification efficiency by fusing a nucleotide sequence and a freely adjustable substitution target and amplifying it at a target gene site, it added. Such factors can improve the effectiveness of the optimization process in product development and is also expected to reduce development time and cost drastically.
"The development of PANAmp, which overcame the limitations of molecular diagnostics, is expected to broaden the scope of molecular diagnostic products,” said Kim Sung-kee 김성기, CEO of Panagene 파나진. “Our company’s platform technology is stepping closer to its goal of becoming a global standard for molecular diagnostics around the world.”
<© Korea Biomedical Review, All rights reserved.>